Daewoong Pharmaceutical, "Stock Price Not to Be Obsessed Over ITC Lawsuit Issue" Stock Price 135,500 KRW (-5.24%)

Daewoong Pharmaceutical is trading at 135,500 KRW as of 10:32 AM on the 8th, down 5.24% from the previous day. The trading volume is 787,397 shares, which is about 27.31% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling medicines such as Urusa and Albis.

On June 3rd, researcher Lee Hyerin from KTB Investment & Securities stated, "The ITC preliminary determination originally scheduled for June 5th has been postponed to July 6th, and the final determination date has also been changed from October 6th to November 6th. Even if the lawsuit result for Daewoong Pharmaceutical turns out negative, the downside is expected to be around 15%, which is not as large as anticipated. Considering that Daewoong and Hanall Biopharma are not directly related to the lawsuit and both have high potential for value increase in their unlisted subsidiaries, and that global peer stock prices continue to rise, the investment attractiveness is high." He set the target price for Daewoong Pharmaceutical at 170,000 KRW.

Over the past five days, individual investors have net bought 31,792 shares of Daewoong Pharmaceutical, while foreigners and institutions have net bought 9,874 shares and net sold 31,725 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.